Our study found statistically significantly lower serum levels of TGF-β1 and TIMP-2 in patients in the long-term follow-up period (>12 months) after breast cancer treatment than in healthy female volunteers, while the level of VEGFR-2 was comparable in these groups. This evidence concerns the gene KDR and breast carcinoma.